GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: LY-3819253 | LY-CoV555 | LY3819253
Compound class:
Antibody
Comment: Bamlanivimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2. It was developed by Eli Lilly, but such is the speed of COVID-19 therapeutic development, there are no peer-reviewed articles that report its design, preclinical or early clinical data.
|
| Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
